Registered title, quoted from ClinicalTrials.gov
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07819591, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically or cytologically confirmed relapsed small-cell lung cancer after failure of platinum-based chemotherapy and PD-1/PD-L1 monoclonal antibody treatment.
Inclusion criterion 3
Recovery of prior anti-tumor therapy toxicities to ≤ Grade 1 (NCI-CTCAE v5.0), except alopecia, fatigue, hyperpigmentation, and stabilized thyroid dysfunction (on hormone replacement) as specified in protocol.
Inclusion criterion 7
Effective contraception from screening through 6 months after end of treatment for all patients with reproductive potential.
Inclusion criterion 14
ECOG performance status 0 or 1.
Inclusion criterion 5
Total bilirubin ≤ 1.5×ULN (≤ 3×ULN if liver metastases); AST and ALT ≤ 2.5×ULN (≤ 5.0×ULN if liver metastases).
Inclusion criterion 10
Creatinine ≤ 1.5×ULN or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault).
Inclusion criterion 11
INR ≤ 1.5; APTT ≤ 1.5×ULN.
Inclusion criterion 12
At least one measurable lesion according to RECIST v1.1.
Inclusion criterion 4
Other malignancy within 5 years, except adequately controlled basal cell carcinoma, cervical CIS, or DCIS >3 years.
Exclusion criterion 13
Women of childbearing potential: negative pregnancy test within 7 days before first dosing and non-lactating.
Inclusion criterion 13
Pregnancy or breastfeeding.
Exclusion criterion 23
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07819591, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients who have signed informed consent and agree to comply with the protocol.
- Age ≥ 18 years.
- Histologically or cytologically confirmed relapsed small-cell lung cancer after failure of platinum-based chemotherapy and PD-1/PD-L1 monoclonal antibody treatment.
- At least one measurable lesion according to RECIST v1.1.
- ECOG performance status 0 or 1.
- Expected survival time ≥ 3 months.
- Recovery of prior anti-tumor therapy toxicities to ≤ Grade 1 (NCI-CTCAE v5.0), except alopecia, fatigue, hyperpigmentation, and stabilized thyroid dysfunction (on hormone replacement) as specified in protocol.
- Adequate cardiac function: left ventricular ejection fraction (LVEF) ≥ 50%.
- Adequate organ function: ANC ≥ 1.5×10\^9/L, platelets ≥ 100×10\^9/L, hemoglobin ≥ 90 g/L.
- Total bilirubin ≤ 1.5×ULN (≤ 3×ULN if liver metastases); AST and ALT ≤ 2.5×ULN (≤ 5.0×ULN if liver metastases).
- Creatinine ≤ 1.5×ULN or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault).
- INR ≤ 1.5; APTT ≤ 1.5×ULN.
- Women of childbearing potential: negative pregnancy test within 7 days before first dosing and non-lactating.
- Effective contraception from screening through 6 months after end of treatment for all patients with reproductive potential.
Exclusion Criteria:
- History of hypersensitivity to paclitaxel micelles, ivonescimab (YS11/YS), or components of these investigational products, or structurally related agents.
- Prior systemic therapy with taxanes and/or anti-VEGF monoclonal antibodies.
- Major surgery within 28 days before first investigational treatment.
- Antitumor treatment within 4 weeks (or 5 half-lives for biologics, whichever is shorter), including chemotherapy, targeted therapy, biologics, immunotherapy, curative radiotherapy, major surgery, or large-field radiotherapy; small-molecule targeted therapy within 5 days before first dose (as protocol details).
- Use of CYP3A/CYP2C inhibitors or inducers within 7 days before first dose, or need to continue during study.
- Use of traditional Chinese anti-tumor herbal medicines within 7 days before first dose, or need to continue during study.
- Ongoing use of drugs known to prolong QT interval or induce torsades during study.
- Symptomatic CNS involvement (including symptomatic brain metastases); brain-metastasis patients previously on steroids must be tapered and off steroids for ≥14 days unless protocol allows exceptions.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
- Tumor encasement/invasion of major thoracoabdominal/other vital vessels judged unsafe for protocol treatment.
- Clinically significant bleeding within 3 weeks before informed consent (e.g., hemoptysis, GI bleeding, bleeding ulcer).
- Inflammatory bowel disease, major bowel resection history, immune-related colitis, bowel obstruction, chronic diarrhea, or Gilbert syndrome.
- Other malignancy within 5 years, except adequately controlled basal cell carcinoma, cervical CIS, or DCIS >3 years.
- Serious cardiac/cerebrovascular disease: NYHA class ≥2 heart failure, acute coronary syndrome within 6 months, or stroke/TIA/hemorrhagic stroke within 6 months.
- Significant arrhythmia (complete LBBB, third-degree AV block, uncontrolled ventricular/atrial arrhythmia; stable controlled arrhythmia exceptions may apply).
- Active unstable thromboembolic disease requiring treatment within 6 months (except >4-week old peripheral line thrombosis).
- Uncontrolled systemic diseases likely to interfere with protocol conduct, including uncontrolled hypertension, diabetes, active bleeding, active hepatitis B/C/HIV (including HBV DNA >10000 copies/mL when HBsAg positive), or other active infection.
- Autoimmune disease requiring systemic treatment in prior 2 years (excluding replacement hormones).
- Current or clinically significant history of ILD, or ILD/grade ≥2 radiation pneumonitis.
- Severe neurologic or psychiatric disease.
- Unhealed wound, ulcer, or fracture within 4 weeks before informed consent.
- Planned or received live vaccine within 28 days before randomization/first dose.
- Pregnancy or breastfeeding.
- Any other condition the investigator judges to make trial participation inappropriate.
Quoted from ClinicalTrials.gov, NCT07819591, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07819591, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.